Redefining outcomes in esophageal cancer surgery: insights from longitudinal Medicare data Authors: Thomas Birdas Published: 2026 Esophagectomy for cancer remains one of the most complex and resource-intensive operations in thoracic surgery, particularly in older patients. While advances in surgical technique, perioperative care, and multimodality therapy have improved short-term outcomes, long-term survival and healthcare utilization remain poorly characterized in national clinical registries. In this context, Blasberg and colleagues (1) present a landmark analysis linking the Society of Thoracic Surgeons General Thoracic Surgery Database (STS GTSD) with Centers for Medicare and Medicaid Services (CMS) data to evaluate longitudinal outcomes following esophagectomy in Medicare beneficiaries. Their work fundamentally expands how surgeons, oncologists, and health systems should conceptualize risk, success, and value in esophageal cancer surgery. The following represents an invited editorial commentary on this study. By analyzing nearly 5,000 patients aged 65 years and older who underwent esophagectomy for cancer between 2012 and 2020, this study provides the most comprehensive assessment to date of short-term mortality, long-term survival, and readmission in this population. Importantly, the authors distinguish predictors of early mortality (≤90 days) from those driving long-term outcomes, allowing for a more clinically meaningful interpretation of risk across the continuum of care. The linkage of the STS GTSD with CMS claims data represents a critical methodological advance. Although the STS database excels at capturing perioperative variables and 30-day outcomes, it lacks longitudinal follow-up. In contrast, CMS data provide long-term mortality and readmission information but without the detailed case-level clinical details. The integration of these data sources enables a better understanding of esophagectomy outcomes. The reported 30- and 90-day mortality rates of 3.8% and 7.5%, respectively, reflect contemporary outcomes at STS-participating centers and underscore that early postoperative mortality remains substantial in elderly patients. Short-term mortality was driven primarily by patient-level factors, including advanced age, cardiopulmonary and renal comorbidities, and impaired functional status. Major postoperative complications—notably reintubation and unplanned return to the operating room—also independently predicted early death. Notably, neither operative approach (open versus minimally invasive) nor procedure type (Ivor Lewis, transhiatal, or three-hole) independently influenced mortality. In contrast, long-term mortality was influenced by tumor biology and treatment response. Pathologic nodal status and T-stage upstaging emerged as the strongest predictors of death beyond 90 days. Patients who were upstaged to pathologic node-positive disease experienced a markedly increased risk of mortality, while those who achieved nodal downstaging following neoadjuvant therapy demonstrated a survival advantage even over patients who were node-negative both clinically and pathologically. These findings highlight the prognostic importance of response to therapy rather than baseline stage alone. One of the more provocative observations was the protective association of higher body mass index on long-term survival. Underweight patients faced significantly worse outcomes, while patients with body mass index (BMI) in the overweight or obese range had improved survival. Although BMI is an imperfect surrogate for nutritional status, this finding suggests that frailty and cancer-associated cachexia may be more clinically relevant than obesity when assessing operative risk in esophageal cancer patients. It reinforces the importance of preoperative nutritional assessment and optimization, particularly in older adults. Long-term readmission emerged as a critical outcome in this study and one deserving of greater emphasis in clinical practice. Two-thirds of patients surviving beyond 90 days were readmitted, with readmission risk increasing dramatically with advancing stage. Patients with pathologic stage III disease faced an almost 80% risk of readmission at 5 years. These readmissions were not associated with operative approach or procedure type but were linked to advanced disease, persistent nodal involvement, and higher physiologic risk. Common causes included infection, pulmonary complications, secondary malignancy, and gastrointestinal obstruction, reflecting both treatment-related morbidity and disease progression. The clinical implications of these findings are profound. First, they argue strongly for a shift in preoperative counseling and shared decision-making. Surgeons should clearly differentiate early physiologic risk from long-term oncologic risk, particularly when counseling elderly patients. While comorbidities and functional status drive early outcomes, tumor response to therapy determines long-term survival and healthcare utilization. Second, the data reinforce the significant role of neoadjuvant therapy and pathologic response in esophageal cancer management. Persistent nodal disease or T-stage upstaging should be viewed as markers of biologically aggressive disease. These patients represent a high-risk population that may benefit from intensified adjuvant therapy, including immunotherapy, and closer postoperative surveillance. In contrast, patients who achieve meaningful downstaging derive a clear survival benefit, validating current multimodality treatment paradigms. Third, the extraordinary burden of long-term readmission highlights the need to reconceptualize survivorship after esophagectomy. For advanced-stage patients, postoperative care should extend beyond routine surgical follow-up to include coordinated survivorship programs integrating oncology, nutrition, pulmonary care, and symptom management. Reducing avoidable hospitalizations may not only improve quality of life but also mitigate the substantial healthcare utilization associated with esophageal cancer. Finally, these findings challenge existing quality metrics. Reliance on 30-day mortality and postoperative complication rates alone fails to capture the true impact of esophagectomy in older adults. Longitudinal outcomes such as 90-day mortality, long-term survival, and readmission provide a more meaningful assessment of value and should be considered in future quality improvement initiatives and policy frameworks. Several limitations of the Blasberg et al. study merit consideration when interpreting these findings. The cohort is restricted to Medicare beneficiaries aged 65 years and older, and it remains uncertain whether these outcome associations hold in younger patients undergoing esophagectomy, who may differ substantially in comorbidity burden, tumor biology, and physiologic reserve. Linkage with CMS administrative claims data introduces the potential for misclassification and limits granularity with respect to oncologic endpoints such as disease recurrence, patterns of systemic therapy, and radiation details. Importantly, incomplete linkage of eligible patients to Medicare data may introduce selection bias—patients successfully linked may differ systematically from those who were not captured, due to differences in Medicare enrollment status or administrative completeness. Finally, residual confounding is likely, particularly in interpreting the associations between neoadjuvant response and long-term survival, as unmeasured variables including performance status trajectory, comorbidity evolution, and center-level practice patterns may influence outcomes. These findings should therefore be considered associative rather than causal. In summary, this study redefines expectations following esophagectomy for cancer in Medicare patients. Early outcomes are dictated by patient physiology and perioperative events, whereas long-term survival and readmission are driven by tumor biology and response to therapy. Improving outcomes will require not only technical excellence in the operating room but also biologically informed oncologic strategies, aggressive patient optimization, and sustained post-discharge engagement. By extending the reach of the STS GTSD through CMS linkage, Blasberg and colleagues provide a powerful framework for advancing quality, value, and patient-centered care in esophageal cancer surgery. Supplementary The article’s supplementary files as Acknowledgments None. Ethical Statement: The author is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Footnotes Provenance and Peer Review: This article was commissioned by the editorial office, Journal of Thoracic Disease. The article has undergone external peer review. Funding: None. Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-0699/coif). The author has no conflicts of interest to declare. References Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-0699/prf Supplementary Materials The article’s supplementary files as